Emerald has two New Chemical Entities (NCEs) in preclinical development; one for the treatment of multiple sclerosis (MS) and scleroderma, also known as systemic sclerosis (SSc) and the other for the treatment of Huntington’s Disease (HD) and Parkinson’s Disease (PD).
The management of Emerald Health Pharmaceuticals (EHP) believes that cannabinoid analogues have the potential to be developed into safe, effective prescription pharmaceutical drugs. The potential ability of cannabis to treat a broad range of health problems and diseases mirrors the wide distribution of cannabinoid receptors present throughout our bodies. This system is called the endocannabinoid system and is responsible for creating homeostasis (i.e., “balance”) in the body and for reducing inflammation, which is the primary cause of many diseases afflicting millions of people worldwide.
EHP leverages the extensive life-science experience of its founders and management, as well as the expertise of its partners, to produce patented new chemical entities (NCEs) derived from cannabis, and to develop the most promising of these NCEs into pharmaceutical drug candidates. The Company currently has two NCEs in preclinical development. One of these NCEs (EHP-101) is derived from cannabidiol (CBD) and is being developed for the treatment of multiple sclerosis (MS) and scleroderma, also known as systemic sclerosis (SSc). The second NCE (EHP-102) is derived from cannabigerol (CBG), and is being developed for the treatment of Huntington’s Disease (HD) and Parkinson’s Disease (PD).